In this study, we explored the hypothesis that modulation of HER2 endocytosis would improve the accumulation of pertuzumab in HER2-positive gastric tumors and allow the use of a pretargeted approach in HER2-positive tumors. This evidence concerns the gene ERBB2 and gastric neoplasm.